Recombinant antigens
S1 (RBD) COVID-19
for SARS-CoV-2
Coronaviruses are enveloped viruses possessing large, trimeric spike glycoproteins (S) required for the recognition of host receptors for many coronaviruses as well as the fusion of viral and host cell membranes for viral entry into cells. During viral egress from infected host cells, some coronavirus S proteins are cleaved into S1 and S2 subunits. The S1 subunit is responsible for host-receptor binding while the S2 subunit contains the membrane-fusion machinery. Thus, S1 subunit contains the receptor-binding domain (RBD), located in the C-terminal region. This domain is used as a biomarker for COVID diagnostic.
- NAME
- S1 (rbd) covid-19
- DESCRIPTION
- S1 Receptor Binding Domain (RBD)
- GEN
- S
- PURITY
- >95% by observation on SDS-PAGE electrophoresis
- Formats
Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format
* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.
References of Recombinant antigen S1 (RBD) COVID-19
Folletos
- Rekom Biotech catalogue
- Recombinant proteins for in vitro diagnosis of human infectious diseases
- Inmunoassay blocker for proteins made in Pichia pastoris
- Recombinant antigens for diagnosis of COVID-19
Videos
- How to reconsitute lyophizated vials
- How to use the inmunoassay blocker for anti-cross-reactive carbohydrate determinants (CCD) antibodies
Evaluaciones
Related proteins
Reagent sheet
- NAME
- S1 (RBD) COVID-19
- DESCRIPTION
- S1 Receptor Binding Domain (RBD)
- PURITY
- >95% by observation on SDS-PAGE electrophoresis
- Formats
Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format
* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.
